Comparison And Development Of Immunohistochemical Diagnostic Criteria For Blastic Plasmacytoid Dendritic Cell Neoplasm.
暂无分享,去创建一个
H. Nakasone | K. Sakamoto | R. Ichinohasama | K. Takeuchi | S. Momose | A. Tonooka | S. Ono | E. Takakuwa | Satoko Baba | K. Ohshima | Yuka Okumura
[1] A. Malhotra,et al. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML. , 2020, Clinical lymphoma, myeloma & leukemia.
[2] F. Jardin,et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? , 2019, Blood advances.
[3] M. Konopleva,et al. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm , 2019, The American journal of surgical pathology.
[4] M. Konopleva,et al. Tagraxofusp in Blastic Plasmacytoid Dendritic‐Cell Neoplasm , 2019, The New England journal of medicine.
[5] J. V. van Dongen,et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping , 2018, Cytometry. Part B, Clinical cytometry.
[6] K. Ohshima,et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response , 2018, Leukemia.
[7] M. Ferrer,et al. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. , 2016, Cancer cell.
[8] L. Pagano,et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches , 2016, British journal of haematology.
[9] W. Vermi,et al. Neoplasms derived from plasmacytoid dendritic cells , 2016, Modern Pathology.
[10] H. Nakasone,et al. ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern , 2016, International Journal of Hematology.
[11] S. Perkins,et al. Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm , 2014, Modern Pathology.
[12] G. Ehninger,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.
[13] T. Petrella,et al. Blastic Plasmacytoid Dendritic Cell Neoplasms: Clinico-immunohistochemical Correlations in a Series of 91 Patients , 2014, The American journal of surgical pathology.
[14] L. Jeffrey Medeiros,et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow , 2013, American journal of hematology.
[15] W. Vermi,et al. BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. , 2013, Blood.
[16] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[17] T. George,et al. Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. , 2012, American journal of clinical pathology.
[18] M. Paulli,et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. , 2011, Blood.
[19] T. Petrella,et al. Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. , 2011, American journal of clinical pathology.
[20] E. Jaffe,et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications , 2010, Haematologica.
[21] L. Cerroni,et al. Cutaneous Manifestations of Blastic Plasmacytoid Dendritic Cell Neoplasm—Morphologic and Phenotypic Variability in a Series of 33 Patients , 2010, The American journal of surgical pathology.
[22] E. Macintyre,et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia , 2009, British journal of haematology.
[23] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[24] S. Pileri,et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. , 2008, Blood.
[25] R. Willemze,et al. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. , 2007, Blood.
[26] M. Herling,et al. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms , 2006, Modern Pathology.
[27] M. Teitell,et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. , 2004, American journal of clinical pathology.
[28] V. Deneys,et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts , 2004, European journal of immunology.
[29] E. Coccia,et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.
[30] R. Gressin,et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. , 2001, Blood.
[31] A. Órfão,et al. CD123 hiDendritic Cell Lymphoma: An Unusual Case of Non-Hodgkin Lymphoma , 1999, Annals of Internal Medicine.
[32] T. Molina,et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC). , 1999, The American journal of surgical pathology.
[33] K. Imai,et al. High expression of CD56 (N‐CAM) in a patient with cutaneous CD4‐positive lymphoma , 1994, American journal of hematology.
[34] R. Gascoyne,et al. The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells , 2006, Leukemia.